Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ECE1 | P42892 | 6/20 | 0.65 |
| ▸ | GHSR | Q92847 | 3/20 | 0.62 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.62 |
| ▸ | ACE | P12821 | 2/20 | 0.56 |
| ▸ | HPGDS | O60760 | 2/20 | 0.55 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14599288 | 0.95 | ECE1 (0.59) | ECE1GHSROPRM1 | |
| SCHEMBL7326281 | 0.92 | GHSR (0.59) | ECE1GHSROPRM1ACEHPGDS | |
| SCHEMBL24122578 | 0.90 | ECE1 (0.67) | ECE1GHSROPRM1ACEHPGDS | |
| SCHEMBL25093063 | 0.90 | ECE1 (0.56) | ECE1GHSROPRM1ACE | |
| SCHEMBL14446365 | 0.88 | ACE (0.59) | ECE1GHSROPRM1ACEALOX15 | |
| SCHEMBL14446078 | 0.88 | ACE (0.59) | ECE1GHSROPRM1ACEALOX15 | |
| SCHEMBL21862858 | 0.86 | ECE1 (0.51) | ECE1GHSROPRM1ACEHPGDS | |
| SCHEMBL19929604 | 0.85 | ECE1 (0.77) | ECE1ACEHPGDS | |
| SCHEMBL23266831 | 0.85 | GHSR (0.56) | ECE1GHSROPRM1ACEALOX15 | |
| SCHEMBL24122594 | 0.85 | ECE1 (0.69) | ECE1GHSRACEALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022266340-A1 | SELF-ASSEMBLING NANOPARTICLES BASED ON AMPHIPHILIC PEPTIDES FOR DRUG DELIVERY APPLICATIONS | VACCITECH NORTH AMERICA, INC. (US) | 2022-12-22 | — | — | WO | disclosed |
| US-20200054741-A1 | PEPTIDE-BASED VACCINES, METHODS OF MANUFACTURING, AND USES THEREOF FOR INDUCING AN IMMUNE RESPONSE | AVIDEA TECHNOLOGIES, INC. (US) | 2020-02-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200054741-A1 | PEPTIDE-BASED VACCINES, METHODS OF MANUFACTURING, AND USES THEREOF FOR INDUCING AN IMMUNE RESPONSE | MYD88, ICOS, CD4 | ECE1 3131/4885GHSR 2065/4885OPRM1 4680/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.